{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:30:45Z","timestamp":1790501445627,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":1439,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Hemophilia Foundation (Stichting Haemophilia)"},{"name":"CSL Behring (unrestricted grant)"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/jth.14319","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T06:40:53Z","timestamp":1540449653000},"page":"2413-2424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Clinically relevant differences between assays for von Willebrand factor activity"],"prefix":"10.1016","volume":"16","author":[{"given":"J.","family":"Boender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3268-5759","authenticated-orcid":false,"given":"J.","family":"Eikenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"van der Bom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Meris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.P.","family":"Laros\u2010van Gorkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.L.","family":"van Heerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Mauser\u2010Bunschoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.M.","family":"de Maat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.W.G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14319_bb0010","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14319_bb0015","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence\u2010based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel\u00a0report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14319_bb0025","first-page":"362","article-title":"Ristocetin\u2013a new tool in the investigation of platelet aggregation","volume":"26","author":"Howard","year":"1971","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1111\/jth.14319_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.V41.5.687.687","article-title":"Ristocetin: a means of differentiating von Willebrand's disease into two groups","volume":"41","author":"Howard","year":"1973","journal-title":"Blood"},{"key":"10.1111\/jth.14319_bb0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet\u2010dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bodo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0040","first-page":"75","article-title":"Laboratory testing for von Willebrand disease: the past, present, and future state of play for von Willebrand factor assays that measure platelet binding activity, with or without ristocetin","volume":"43","author":"Just","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.14319_bb0045","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1538-7836.2009.03594.x","article-title":"Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function","volume":"7","author":"Flood","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"Flood","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.14319_bb0055","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1055\/s-0038-1660153","article-title":"Registry of monoclonal antibodies to factor VIII and von Willebrand factor. International Committee on Thrombosis and Haemostasis","volume":"54","author":"Goodall","year":"1985","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0060","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1055\/s-0038-1657727","article-title":"von Willebrand factor activity detected in a monoclonal antibody\u2010based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use","volume":"78","author":"Murdock","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/ijlh.12087","article-title":"Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease","volume":"35","author":"Verfaillie","year":"2013","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.14319_bb0070","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.14319_bb0075","first-page":"66","article-title":"ECAT foundation \u2010 external quality control for assays and tests with a focus on thrombosis and haemostasis survey","volume":"1","author":"Meijer","year":"2017","journal-title":"Survey Report 2017\u2010M1"},{"key":"10.1111\/jth.14319_bb0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1160\/TH12-04-0244","article-title":"Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease","volume":"108","author":"de Wee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0085","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Sanders","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14319_bb0090","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/j.1538-7836.2010.04029.x","article-title":"Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol","volume":"8","author":"Hillarp","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0095","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1177\/1076029610379848","article-title":"Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease","volume":"17","author":"Trossaert","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.14319_bb0100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jth.13243","article-title":"Developments in the diagnostic procedures for von Willebrand disease","volume":"14","author":"De Jong","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH14-02-0108","article-title":"Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance","volume":"112","author":"de Maistre","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14319_bb0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.thromres.2015.12.010","article-title":"Evaluation of a von Willebrand factor three test panel and chemiluminescent\u2010based assay system for identification of, and therapy monitoring in, von Willebrand disease","volume":"141","author":"Favaloro","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.14319_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.12218","article-title":"Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin","volume":"36","author":"Graf","year":"2014","journal-title":"Int J Lab Hematol"},{"key":"10.1111\/jth.14319_bb0120","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1111\/hae.12443","article-title":"Discrepancy in von Willebrand factor activity determined by ristocetin cofactor and immunotubidometric assays","volume":"20","author":"Reilly\u2010Stitt","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14319_bb0125","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/hae.12862","article-title":"von Willebrand factor activity assay errors","volume":"22","author":"Bowyer","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.14319_bb0130","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14319_bb0135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cca.2009.12.006","article-title":"Prevalence of human anti\u2010mouse antibodies (HAMAs) in routine examinations","volume":"411","author":"Koshida","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jth.14319_bb0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"de Jong","year":"2017","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622029609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622029609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14319\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:22:50Z","timestamp":1761535370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622029609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1538783622029609"],"URL":"https:\/\/doi.org\/10.1111\/jth.14319","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically relevant differences between assays for von Willebrand factor activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}